Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Jaguar Health, Inc.

< Previous 1 2 3 Next >
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
European Medicines Agency Grants Orphan Drug Designation for Crofelemer to Napo EU, Jaguar Health’s Italian Subsidiary, for Short Bowel Syndrome
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company’s Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health Reports 2021 Third Quarter Financial Results
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Tickers JAGX
Jaguar Health's Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health to Host Investor Webcast Monday, November 15th at 8:30 AM Eastern Time Regarding Q3 2021 Financials & Business Updates
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer
From Jaguar Health, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Tickers JAGX
Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A. has Closed
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Italian Government Clears Merger Plan of Dragon SPAC S.p.A. and Jaguar Health's Italian Subsidiary Napo EU S.p.A. for Closing
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award
From Jaguar Health, Inc.
Via AccessWire
Topics Death
Exposures Death Product Safety
Tickers JAGX
Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Tickers JAGX
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.